ICU Medical’s (ICUI) Hold Rating Reiterated at Needham & Company LLC

ICU Medical (NASDAQ:ICUI)‘s stock had its “hold” rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports.

A number of other brokerages have also issued reports on ICUI. KeyCorp increased their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Raymond James raised their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Jefferies Financial Group initiated coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Stock Down 1.6 %

ICUI opened at $171.96 on Wednesday. The stock has a market cap of $4.20 billion, a price-to-earnings ratio of -37.63 and a beta of 0.66. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The firm’s fifty day moving average is $176.32 and its 200 day moving average is $142.19. ICU Medical has a fifty-two week low of $82.82 and a fifty-two week high of $196.26.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, beating the consensus estimate of $0.88 by $0.35. ICU Medical had a positive return on equity of 5.04% and a negative net margin of 4.74%. The business had revenue of $580.07 million for the quarter, compared to the consensus estimate of $574.77 million. On average, sell-side analysts forecast that ICU Medical will post 3.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares of the company’s stock, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,096,771.78. This represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,502 shares of company stock valued at $6,573,496 in the last three months. Corporate insiders own 6.70% of the company’s stock.

Institutional Trading of ICU Medical

Institutional investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd purchased a new stake in shares of ICU Medical in the third quarter valued at $72,000. Captrust Financial Advisors raised its position in ICU Medical by 54.2% in the 3rd quarter. Captrust Financial Advisors now owns 2,969 shares of the medical instruments supplier’s stock worth $541,000 after purchasing an additional 1,043 shares during the period. Martingale Asset Management L P bought a new stake in ICU Medical in the third quarter worth about $255,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ICU Medical by 4.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,742 shares of the medical instruments supplier’s stock valued at $7,788,000 after buying an additional 1,751 shares during the period. Finally, Public Sector Pension Investment Board grew its stake in shares of ICU Medical by 15.1% during the third quarter. Public Sector Pension Investment Board now owns 51,854 shares of the medical instruments supplier’s stock valued at $9,449,000 after buying an additional 6,800 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.